ofatumumab
ofatumumab is an intervention with 121 clinical trials. Currently 17 active trials ongoing. Historical success rate of 79.6%.
Success Metrics
Based on 78 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
57
Mid Stage
28
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
78.8%
78 of 99 finished
21.2%
21 ended early
17
trials recruiting
121
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Characterizing the Use of Ofatumumab in a Real World Setting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Switch to Ofatumumab and Level of Immunoglobulins
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Clinical Trials (121)
Characterizing the Use of Ofatumumab in a Real World Setting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Switch to Ofatumumab and Level of Immunoglobulins
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 121